

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL LLC,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case IPR2020-00324
Patent 8,114,833

**PATENT OWNER MANDATORY NOTICE INFORMATION
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Novo Nordisk A/S (“Novo Nordisk”), hereby files its Mandatory Notices:

A. Real Party-in-Interest (§ 42.8(b)(1))

The following real parties-in-interest are identified: Novo Nordisk A/S, Novo Nordisk Inc., Novo Holdings A/S, and Novo Nordisk Foundation.

B. Related Matters (§ 42.8(b)(2))

Patent Owner is aware of the following district court litigations involving U.S. Patent No. 8,114,833: *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-01551-CFC (D. Del.); *Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC*, No. 19-cv-164 (N.D. W. Va.). Case No. 19-cv-01551-CFC is currently pending. Case No. 19-cv-164 has been voluntarily dismissed.

U.S. Patent Application No. 16/260,204, which is pending and was filed on January 29, 2019, claims the benefit of U.S. Application No. 11/435,977, which is the application that issued as U.S. Patent No. 8,114,833.

C. Counsel and Service Information (§§ 42.8(b)(3) and (4))

Patent Owner identifies its lead and backup counsel as shown below:

Lead Counsel	Backup Counsel
Jeffrey J. Oelke FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) joelke@fenwick.com USPTO Reg. No. 37,409	Ryan P. Johnson (<i>pro hac vice</i> to be sought) FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) ryan.johnson@fenwick.com Laura T. Moran (<i>pro hac vice</i> to be sought) FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 430-2600 (tel) (650) 938-5200 (fax) laura.moran@fenwick.com

Please address all correspondence to the lead and backup counsel at the above addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic service to the e-mail addresses above for lead and backup counsel and to Novo833IPR@fenwick.com.

D. Patent Owner Preliminary Response

Patent Owner reserves the right to file a preliminary response at a separate date.

E. Patent Owner Power of Attorney

A Power of Attorney to transact all business in the United States Patent and Trademark office in connection with above-referenced *Inter Partes* Review from Patent Owner Novo Nordisk A/S to the above-designated counsel at Fenwick &

West LLP is being filed concurrently with these Mandatory Notices.

Dated: January 9, 2020

Respectfully submitted,

/Jeffrey J. Oelke/

Jeffrey J. Oelke (Reg. No. 37,409)

FENWICK & WEST LLP

902 Broadway, Suite 14

New York, NY 10010

(212) 430-2600 (tel)

joelke@fenwick.com

Counsel for Novo Nordisk A/S

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing Patent Owner Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on **January 9, 2020**, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Brandon M. White
Lara Dueppen
Perkins Coie LLP
white-ptab@perkinscoie.com
dueppen-ptab@perkinscoie.com

Date: January 9, 2020

Respectfully submitted,

/Jeffrey J. Oelke/
Jeffrey J. Oelke (Reg. No. 37,409)

Counsel for Novo Nordisk A/S